Biosimilar Landscape in Japan: Impact of PMDA Updates & SAKIGAKE 2024
This article delves into the impact of recent PMDA updates and the SAKIGAKE initiative on the biosimilar market in Japan, highlighting implications for drugs like adalimumab.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 21, 2026
Key Takeaways
- Regulatory shift: The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has revised its biosimilar guidelines, eliminating the requirement for mandatory enrollment of Japanese subjects in clinical trials.
- Market drivers: The Ministry of Health, Labour and Welfare (MHLW) is actively promoting biosimilar adoption through specific market share targets.
- Accelerated approval: The SAKIGAKE designation facilitates faster development and approval of innovative biosimilars in Japan.
- Future impact: These changes are expected to accelerate biosimilar innovation and market penetration in Japan.
Japan's biosimilar market is set for transformation following the PMDA biosimilar approval process updates in January 2024, which reduce clinical data requirements, and MHLW’s market share targets. These changes, combined with the SAKIGAKE designation, aim to accelerate biosimilar innovation and market penetration within Japan.
Drug Overview
Biosimilars are follow-on versions of biologics, developed after the original product's patent expires. While the specific mechanism of action depends on the reference biologic, biosimilars generally work by mimicking the therapeutic effect of the originator drug. They are indicated for the same conditions as their reference products.
Clinical Insights
No specific clinical trial data was provided in the source materials.
Regulatory Context
In January 2024, the PMDA revised its biosimilars guidelines, eliminating the requirement for mandatory enrollment of Japanese subjects in clinical trials. The SAKIGAKE designation offers an accelerated approval pathway for innovative biosimilars.
Market Impact
The PMDA's regulatory revisions are expected to enhance biosimilar uptake and competition in the Japanese market. By reducing clinical data requirements, the agency is facilitating faster approval and broader access to biosimilars. The MHLW's market share targets further incentivize biosimilar adoption, potentially leading to cost savings for healthcare payers and patients. The SAKIGAKE designation provides an accelerated development and approval pathway for innovative biosimilars, differentiating these products by enabling faster market access compared to traditional regulatory routes. Why it matters: Regulatory easing and strategic government targets are expected to enhance biosimilar uptake and competition in the Japanese market, facilitating faster approval and broader access to biosimilars. The SAKIGAKE designation provides an accelerated development and approval pathway for innovative biosimilars, differentiating these products by enabling faster market access compared to traditional regulatory routes. Compared with previous regulations, the updated guidelines reduce the clinical data burden for biosimilar developers.
Future Outlook
The regulatory changes are predicted to accelerate biosimilar approvals in Japan, facilitated by the SAKIGAKE designation's expedited pathways. What to watch next: Emerging trends in biosimilar manufacturing scale and cost optimization in Japan, potential challenges including interchangeability, physician acceptance, and patient education, long-term impact on Japan’s biologics market and healthcare expenditure, and opportunities for multinational and domestic biosimilar developers.
Frequently Asked Questions
What is the significance of the PMDA's January 2024 guideline revisions for biosimilars?
The PMDA's revisions eliminate the requirement for mandatory enrollment of Japanese subjects in biosimilar clinical trials, reducing the clinical data burden for manufacturers and potentially accelerating the approval process.
How does the MHLW plan to increase biosimilar uptake in Japan?
The MHLW has set specific market share targets to encourage the adoption of biosimilars, which is expected to drive increased market penetration.
What is the SAKIGAKE designation and how does it benefit biosimilar development?
The SAKIGAKE designation supports accelerated development and approval of innovative biosimilars, providing a regulatory pathway for faster market access.
References
- (Source 1)
Asia-Pacific Editor
Dr. Yuki Tanaka is an oncologist specializing in Asian pharmaceutical markets and regulatory harmonization. Former PMDA reviewer with expertise in bridging studies and ethnic factors....
